Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
His resignation would be effective from March 18, 2024
Almost 300 million people globally have chronic hepatitis B
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Roche and its subsidiary TIB Molbiol have developed three different LightMix Modular Virus kits for the detection of the virus
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Subscribe To Our Newsletter & Stay Updated